行情

GENE

GENE

基因技术
NASDAQ

实时行情|Nasdaq Last Sale

1.870
+0.070
+3.89%
交易中 12:45 11/14 EST
开盘
1.850
昨收
1.800
最高
1.870
最低
1.820
成交量
1.08万
成交额
--
52周最高
6.32
52周最低
1.560
市值
206.02万
市盈率(TTM)
-0.4660
分时
5日
1月
3月
1年
5年

EPS

GENE 新闻

  • Genetic Technologies Offers Shareholder Update On Recent Achievements, Upcoming Milestones
  • Benzinga.11/05 12:57
  • Genetic Technologies Provides Shareholder Update on Recent Achievements and Upcoming Milestones
  • GlobeNewswire.11/05 12:00
  • Genetic Technologies Reports issue of 928,397,236 Ordinary Shares in the Company on October 28 2019
  • Benzinga.10/31 08:26
  • 成都市贝瑞和康基因技术股份有限公司
  • 中国证券报.10/30 22:09

更多

所属板块

医疗设施与服务
+0.16%
医疗保健提供商与服务
+0.20%

热门股票

名称
价格
涨跌幅

GENE 简况

Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company's subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. Genetic Technologies Corporation Pty. Ltd. is engaged in genetic testing. The Company has launched the BREVAGen test across the United States through Phenogen Sciences Inc.
展开

Webull提供Genetic Technologies Limited (ADR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。